SGN-CD123A is an antibody-drug conjugate (ADC) targeted to CD123, a protein found on the surface of myeloid leukemia cells, including leukemic stem cells, in most patients with acute myeloid leukemia (AML). It uses our newest ADC technology, where the anti-CD123 antibody is attached with a stable linker to two molecules of a highly potent DNA crosslinking agent called a PBD (pyrrolobenzodiazepine) dimer.
This antibody-drug conjugate (ADC) is designed to be stable in the bloodstream, and to release its cytotoxic agent once inside the CD123-expressing tumor cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing the antitumor activity.
Phase 1 trial evaluating safety and antitumor activity of SGN-CD123A in patients with AML.